SEC Comment Letter for TuHURA Biosciences, (HURA) — Feb 11, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: Feb. 11, 2019 · CIK: 0001498382 · Accession: 0000000000-19-001797
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229020
Letter
February 8, 2019 Scott Praill Chief Financial Officer DelMar Pharmaceuticals, Inc. Suite 720-999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Re:DelMar Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 26, 2018 File No. 333-229020 Dear Mr. Praill: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Steven M. Skolnick
Show Raw Text
February 8, 2019
Scott Praill
Chief Financial Officer
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5
Re:DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed December 26, 2018
File No. 333-229020
Dear Mr. Praill:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven M. Skolnick